Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Latest News

FDA Seeks to Withdraw Melphalan Flufenamide for Relapsed/Refractory Multiple Myeloma
FDA Seeks to Withdraw Melphalan Flufenamide for Relapsed/Refractory Multiple Myeloma

December 7th 2022

Oncopeptides AB announced December 7, 2022, that the FDA has asked the company to withdraw melphalan flufenamide from the US market.

A Breakthrough for the “Lab Brat”
A Breakthrough for the “Lab Brat”

December 5th 2022

Belantamab Mafodotin to Be Withdrawn From US Market for Relapsed/Refractory Myeloma
Belantamab Mafodotin to Be Withdrawn From US Market for Relapsed/Refractory Myeloma

November 22nd 2022

Standard Induction Evolves in Transplant-Eligible and -Ineligible Multiple Myeloma
Standard Induction Evolves in Transplant-Eligible and -Ineligible Multiple Myeloma

November 16th 2022

State of Science Summit- Multiple Myeloma: Chaired by Ajai Chari, MD
State of Science Summit- Multiple Myeloma: Chaired by Ajai Chari, MD

November 12th 2022

Video Series
Video Interviews
Podcasts

More News